Severe asthma: adding new evidence – Latin American Thoracic Society
This document constitutes a summary of the clinical practice guidelines (CPGs) prepared at the initiative of the Latin American Thoracic Society (ALAT). Due to new evidence in the treatment of severe asthma, it was agreed to select six clinical questions, and the corresponding recommendations are pr...
- Autores:
-
Garcia, Gabriel
Bergna, Miguel
Vasquez, Juan C.
Cano Salas, Maria C.
Miguel, Jose L.
Celis-Preciado, Carlos Andrés
Acuña Izcaray, Agustin
Barros Monge, Manuel
Garcia Batista, Natalia
Zabert, Ignacio
Mayorga, Jose L.
Casanova Mendoza, Renato
Gutierrez, Martha
Montero Arias, Maria F.
Urtecho Perez, Luzcenelia
Antúnez, Miguel
Williams Derby, Victoria
Villatoro Azméquita, Alejandra
Motiño, Luis
De Oliveira, M. Alenita
Rey Sanchez, Diana
Arroyo, Marisol
Rodriguez, Mario
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2021
- Institución:
- Pontificia Universidad Javeriana
- Repositorio:
- Repositorio Universidad Javeriana
- Idioma:
- eng
- OAI Identifier:
- oai:repository.javeriana.edu.co:10554/59921
- Acceso en línea:
- https://openres.ersjournals.com/content/7/1/00318-2020
http://hdl.handle.net/10554/59921
https://doi.org/10.1183/23120541.00318-2020
- Palabra clave:
- Rights
- License
- Atribución-NoComercial 4.0 Internacional
id |
JAVERIANA2_56df64beb0a50e21d36579cb17b033f4 |
---|---|
oai_identifier_str |
oai:repository.javeriana.edu.co:10554/59921 |
network_acronym_str |
JAVERIANA2 |
network_name_str |
Repositorio Universidad Javeriana |
repository_id_str |
|
spelling |
Atribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2Garcia, GabrielBergna, MiguelVasquez, Juan C.Cano Salas, Maria C.Miguel, Jose L.Celis-Preciado, Carlos AndrésAcuña Izcaray, AgustinBarros Monge, ManuelGarcia Batista, NataliaZabert, IgnacioMayorga, Jose L.Casanova Mendoza, RenatoGutierrez, MarthaMontero Arias, Maria F.Urtecho Perez, LuzceneliaAntúnez, MiguelWilliams Derby, VictoriaVillatoro Azméquita, AlejandraMotiño, LuisDe Oliveira, M. AlenitaRey Sanchez, DianaArroyo, MarisolRodriguez, MarioPontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. NeumologíaPontificia Universidad Javeriana. Facultad de Medicina. Hospital Universitario San IgnacioCelis-Preciado, Carlos Andrés2022-05-31T15:34:08Z2022-05-31T15:34:08Z2021-01-18https://openres.ersjournals.com/content/7/1/00318-20202312-0541http://hdl.handle.net/10554/59921https://doi.org/10.1183/23120541.00318-2020instname:Pontificia Universidad Javerianareponame:Repositorio Institucional - Pontificia Universidad Javerianarepourl:https://repository.javeriana.edu.coThis document constitutes a summary of the clinical practice guidelines (CPGs) prepared at the initiative of the Latin American Thoracic Society (ALAT). Due to new evidence in the treatment of severe asthma, it was agreed to select six clinical questions, and the corresponding recommendations are provided herein. After considering the quality of the evidence, the balance between desirable and undesirable impacts and the feasibility and acceptance of procedures, the following recommendations were established. 1) We do not recommend the use of an inhaled corticosteroid (ICS) plus formoterol as rescue medication in the treatment of severe asthma. 2) We suggest performing many more high-quality randomised studies to evaluate the efficacy and safety of tiotropium in patients with severe asthma. 3) Omalizumab is recommended in patients with severe uncontrolled allergic asthma with serum IgE levels above 30 IU. 4) Anti-interleukin (IL)-5 drugs are recommended in patients with severe uncontrolled eosinophilic asthma (cut-off values above 150 cells·µL−1 for mepolizumab and above 400 cells·µL−1 for reslizumab). 5) Benralizumab is recommended in adult patients with severe uncontrolled eosinophilic asthma (cut-off values above 300 cells·µL−1). 6) Dupilumab is recommended in adult patients with severe uncontrolled allergic and eosinophilic asthma and in adult patients with severe corticosteroid-dependent asthma.Q2Q2Pacientes con Asma severahttps://orcid.org/0000-0001-8405-4513Revista Internacional - IndexadaA1NoPDFapplication/pdfengSevere asthma: adding new evidence – Latin American Thoracic SocietyArtículo de revisiónhttp://purl.org/coar/resource_type/c_6501116ERJ Open Research71ORIGINALa3682.pdfapplication/pdf591154http://repository.javeriana.edu.co/bitstream/10554/59921/1/a3682.pdfcf2ec1fa579389ea99b45f245012d473MD51open accessTHUMBNAILa3682.pdf.jpga3682.pdf.jpgIM Thumbnailimage/jpeg11273http://repository.javeriana.edu.co/bitstream/10554/59921/2/a3682.pdf.jpg19ae536a4b6ffe22b18a23ae0e3faa59MD52open access10554/59921oai:repository.javeriana.edu.co:10554/599212023-05-19 10:26:01.846Repositorio Institucional - Pontificia Universidad Javerianarepositorio@javeriana.edu.co |
dc.title.none.fl_str_mv |
Severe asthma: adding new evidence – Latin American Thoracic Society |
title |
Severe asthma: adding new evidence – Latin American Thoracic Society |
spellingShingle |
Severe asthma: adding new evidence – Latin American Thoracic Society |
title_short |
Severe asthma: adding new evidence – Latin American Thoracic Society |
title_full |
Severe asthma: adding new evidence – Latin American Thoracic Society |
title_fullStr |
Severe asthma: adding new evidence – Latin American Thoracic Society |
title_full_unstemmed |
Severe asthma: adding new evidence – Latin American Thoracic Society |
title_sort |
Severe asthma: adding new evidence – Latin American Thoracic Society |
dc.creator.fl_str_mv |
Garcia, Gabriel Bergna, Miguel Vasquez, Juan C. Cano Salas, Maria C. Miguel, Jose L. Celis-Preciado, Carlos Andrés Acuña Izcaray, Agustin Barros Monge, Manuel Garcia Batista, Natalia Zabert, Ignacio Mayorga, Jose L. Casanova Mendoza, Renato Gutierrez, Martha Montero Arias, Maria F. Urtecho Perez, Luzcenelia Antúnez, Miguel Williams Derby, Victoria Villatoro Azméquita, Alejandra Motiño, Luis De Oliveira, M. Alenita Rey Sanchez, Diana Arroyo, Marisol Rodriguez, Mario |
dc.contributor.author.none.fl_str_mv |
Garcia, Gabriel Bergna, Miguel Vasquez, Juan C. Cano Salas, Maria C. Miguel, Jose L. Celis-Preciado, Carlos Andrés Acuña Izcaray, Agustin Barros Monge, Manuel Garcia Batista, Natalia Zabert, Ignacio Mayorga, Jose L. Casanova Mendoza, Renato Gutierrez, Martha Montero Arias, Maria F. Urtecho Perez, Luzcenelia Antúnez, Miguel Williams Derby, Victoria Villatoro Azméquita, Alejandra Motiño, Luis De Oliveira, M. Alenita Rey Sanchez, Diana Arroyo, Marisol Rodriguez, Mario |
dc.contributor.corporatename.spa.fl_str_mv |
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Neumología |
dc.contributor.corporatename.none.fl_str_mv |
Pontificia Universidad Javeriana. Facultad de Medicina. Hospital Universitario San Ignacio |
dc.contributor.javerianateacher.none.fl_str_mv |
Celis-Preciado, Carlos Andrés |
description |
This document constitutes a summary of the clinical practice guidelines (CPGs) prepared at the initiative of the Latin American Thoracic Society (ALAT). Due to new evidence in the treatment of severe asthma, it was agreed to select six clinical questions, and the corresponding recommendations are provided herein. After considering the quality of the evidence, the balance between desirable and undesirable impacts and the feasibility and acceptance of procedures, the following recommendations were established. 1) We do not recommend the use of an inhaled corticosteroid (ICS) plus formoterol as rescue medication in the treatment of severe asthma. 2) We suggest performing many more high-quality randomised studies to evaluate the efficacy and safety of tiotropium in patients with severe asthma. 3) Omalizumab is recommended in patients with severe uncontrolled allergic asthma with serum IgE levels above 30 IU. 4) Anti-interleukin (IL)-5 drugs are recommended in patients with severe uncontrolled eosinophilic asthma (cut-off values above 150 cells·µL−1 for mepolizumab and above 400 cells·µL−1 for reslizumab). 5) Benralizumab is recommended in adult patients with severe uncontrolled eosinophilic asthma (cut-off values above 300 cells·µL−1). 6) Dupilumab is recommended in adult patients with severe uncontrolled allergic and eosinophilic asthma and in adult patients with severe corticosteroid-dependent asthma. |
publishDate |
2021 |
dc.date.created.none.fl_str_mv |
2021-01-18 |
dc.date.accessioned.none.fl_str_mv |
2022-05-31T15:34:08Z |
dc.date.available.none.fl_str_mv |
2022-05-31T15:34:08Z |
dc.type.local.spa.fl_str_mv |
Artículo de revisión |
dc.type.coar.none.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
format |
http://purl.org/coar/resource_type/c_6501 |
dc.identifier.none.fl_str_mv |
https://openres.ersjournals.com/content/7/1/00318-2020 |
dc.identifier.issn.none.fl_str_mv |
2312-0541 |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/10554/59921 |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1183/23120541.00318-2020 |
dc.identifier.instname.spa.fl_str_mv |
instname:Pontificia Universidad Javeriana |
dc.identifier.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional - Pontificia Universidad Javeriana |
dc.identifier.repourl.spa.fl_str_mv |
repourl:https://repository.javeriana.edu.co |
url |
https://openres.ersjournals.com/content/7/1/00318-2020 http://hdl.handle.net/10554/59921 https://doi.org/10.1183/23120541.00318-2020 |
identifier_str_mv |
2312-0541 instname:Pontificia Universidad Javeriana reponame:Repositorio Institucional - Pontificia Universidad Javeriana repourl:https://repository.javeriana.edu.co |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationstartpage.none.fl_str_mv |
1 |
dc.relation.citationendpage.none.fl_str_mv |
16 |
dc.relation.ispartofjournal.none.fl_str_mv |
ERJ Open Research |
dc.relation.citationvolume.none.fl_str_mv |
7 |
dc.relation.citationissue.none.fl_str_mv |
1 |
dc.rights.licence.*.fl_str_mv |
Atribución-NoComercial 4.0 Internacional |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc/4.0/ |
dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
rights_invalid_str_mv |
Atribución-NoComercial 4.0 Internacional http://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
dc.format.spa.fl_str_mv |
PDF |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
institution |
Pontificia Universidad Javeriana |
bitstream.url.fl_str_mv |
http://repository.javeriana.edu.co/bitstream/10554/59921/1/a3682.pdf http://repository.javeriana.edu.co/bitstream/10554/59921/2/a3682.pdf.jpg |
bitstream.checksum.fl_str_mv |
cf2ec1fa579389ea99b45f245012d473 19ae536a4b6ffe22b18a23ae0e3faa59 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional - Pontificia Universidad Javeriana |
repository.mail.fl_str_mv |
repositorio@javeriana.edu.co |
_version_ |
1808389853586391041 |